The Traderszone Network

Published in TZ Latest News 17 October, 2017 by The TZ Newswire Staff

Novartis drug Revolade® shows long-term disease control for chronic/persistent immune thrombocytopenia (ITP)

Basel, October 18, 2017 – Novartis today announced long-term study results supporting the positive safety and efficacy of Revolade (eltrombopag) in adults with chronic/persistent (enrolling patients that were 6 or more months from diagnosis) immune (idiopathic) thrombocytopenia (ITP) were published online in Blood. The EXTEND study found that a majority of patients maintained a substantial clinical response and many no longer needed concomitant ITP medications.

read more